✦ LIBER ✦

Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY)

✍ Scribed by Sergio Bracarda; Camillo Porta; Corrado Boni; Armando Santoro; Claudia Mucciarini; Antonio Pazzola; Enrico Cortesi; Donatello Gasparro; Roberto Labianca; Francesco Di Costanzo; Alfredo Falcone; Michela Cinquini; Claudia Caserta; Chiara Paglino; Verena De Angelis

Book ID: 118440945
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 282 KB
Volume: 63
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2012.08.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SORAFENIB PLUS INTERFERON-α2A IN METASTA

SORAFENIB PLUS INTERFERON-α2A IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM RAPSODY (GOIRC STUDY 0681), A RANDOMISED PROSPECTIVE PHASE II TRIAL OF TWO DIFFERENT TREATMENT SCHEDULES

✍ S. Bracarda; C. Porta; C. Boni; A. Santoro; F. Artioli; A. Contu; L. Mentuccia; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Randomized Phase II Trial of First-Line

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Coplen, D.E. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 69 KB

Granulocyte/macrophage-colony-stimulatin

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study

✍ Jörg Westermann; Gernot Reich; Joachim Kopp; Ulrike Haus; Bernd Dörken; Antonio 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 143 KB

Stratification by risk factors predicts

Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

✍ Janice P. Dutcher; Jason P. Fine; Robert L. Krigel; Barbara A. Murphy; Paul L. S 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 109 KB

883 POSTER Phase I trial of sorafenib (B

883 POSTER Phase I trial of sorafenib (BAY 43–9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

A RANDOMIZED PHASE II TRIAL COMPARING TW

A RANDOMIZED PHASE II TRIAL COMPARING TWO DIFFERENT SEQUENCE COMBINATIONS OF AUTOLOGOUS VACCINE AND HUMAN RECOMBINANT INTERFERON γ AND HUMAN RECOMBINANT INTERFERON α2B THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: CLINICAL OUTCOME AND ANALYSIS OF IMMUNOLOGICAL PARAMETERS

✍ SCHWAAB, THOMAS; HEANEY, JOHN A.; SCHNED, ALAN R.; HARRIS, ROBERT D.; COLE, BERN 📂 Article 📅 2000 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 113 KB